ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1BDX | BECTON DICKINSON & CO | Healthcare | $58.76B | 28.84% |
2CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $16.33B | 8.01% |
3SOLV | SOLVENTUM CORP | Healthcare | $15.07B | 7.40% |
4PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $9.08B | 4.46% |
5TXG | 10X GENOMICS INC | Healthcare | $7.77B | 3.82% |
6ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 3.27% |
7TFX | TELEFLEX INC | Healthcare | $6.07B | 2.98% |
8PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 2.60% |
9DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 2.56% |
10ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 2.18% |
11TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 2.07% |
12CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 2.03% |
13XENE | XENON PHARMACEUTICALS INC | Healthcare | $4.03B | 1.98% |
14OGN | ORGANON & CO | Healthcare | $3.65B | 1.79% |
15VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $3.46B | 1.70% |
16IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 1.49% |
17RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 1.26% |
18PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 1.10% |
19CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.24B | 1.10% |
20IMNM | IMMUNOME INC | Healthcare | $2.21B | 1.08% |
21BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 1.05% |
22FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.95% |
23ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.87B | 0.92% |
24XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.90% |
25CERT | CERTARA INC | Healthcare | $1.82B | 0.89% |
26SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.84% |
27STOK | STOKE THERAPEUTICS INC | Healthcare | $1.71B | 0.84% |
28TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.78% |
29ABSI | ABSCI CORP | Healthcare | $1.57B | 0.77% |
30NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.73% |
31NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.71% |
32KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.70% |
33OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.68% |
34INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.63% |
35NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.27B | 0.62% |
36NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.58% |
37AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.53% |
38GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $796M | 0.39% |
39ALMS | ALUMIS INC | Healthcare | $793M | 0.39% |
40QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.36% |
41KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.34% |
42DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.33% |
43CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $595M | 0.29% |
44MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.27% |
45RGNX | REGENXBIO INC | Healthcare | $531M | 0.26% |
46ARVN | ARVINAS INC | Healthcare | $450M | 0.22% |
47AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.22% |
48LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.19% |
49EMBC | EMBECTA CORP | Healthcare | $364M | 0.18% |
50TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.17% |
51EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.15% |
52ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.12% |
53SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.12% |
54UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.12% |
55RXST | RXSIGHT INC | Healthcare | $226M | 0.11% |
56AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.10% |
57TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.10% |
58KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.10% |
59KRRO | KORRO BIO INC | Healthcare | $196M | 0.10% |
60RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.10% |
61OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.08% |
62STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.08% |
63INGN | INOGEN INC | Healthcare | $146M | 0.07% |
64SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.06% |
65CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.05% |
66RLYB | RALLYBIO CORP | Healthcare | $84M | 0.04% |
67ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.04% |
68NTRB | NUTRIBAND INC | Healthcare | $73M | 0.04% |
69YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.03% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $203.76B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 83% toward Large, 73% toward Growth. +11% unclassified (14 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 69 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 69 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 77.5% | 38.5% |
| 3 yearsp.a. | 30.8% | 2.3% |
| 5 yearsp.a. | 16.0% | 11.7% |
| 10 yearsp.a. | 11.3% | 2.7% |
| Since inceptionp.a. | 9.0% | 2.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 75.6% | 36.1% |
| 2025 | 30.6% | -12.3% |
| 2024 | -9.0% | -5.5% |
| 2023 | -4.3% | 12.5% |
| 2022 | 3.3% | 22.6% |
| 2021 | -2.8% | -9.7% |
| 2020 | 40.4% | 26.9% |
| 2019 | 9.0% | -19.9% |
| 2018 | -12.5% | 6.4% |
| 2017 | 8.9% | -16.8% |
| 2016 | 0.7% | 11.2% |
| 2015 | 10.5% | -5.4% |
| 2014 | 18.6% | -10.1% |
| 2013 | 34.2% | -17.6% |
| 2012 | 31.4% | 13.4% |
| 2011 | 7.6% | 3.9% |
| 2010 | 17.3% | 11.8% |
| 2009 | 18.8% | -12.8% |
| 2008 | -15.0% | 15.3% |
| 2007 | -3.5% | -19.7% |
| 2006 | 19.0% | 20.1% |
| 2005 | 1.0% | -17.8% |
| 2004 | -5.1% | 3.2% |
| 2003 | 17.1% | -14.9% |
| 2002 | -38.1% | 9.4% |
| 2001 | -14.2% | 17.5% |
| 2000 | 73.6% | 37.2% |
| 1999 | 8.4% | 15.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Sales Discipline Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Sales Discipline signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.